Tolvaptan in portal hypertension: real life experience

Tolvaptan (TVP) is a selective antagonist of vasopressin receptors, approved for the treatment of hyponatremia in SIADH, congestive heart failure (CHF) and cirrhosis. We retrospectively reviewed all cases where TVP was used in a tertiary hospital (January 2012- January 2017). Our aim was to study th...

Full description

Saved in:

Bibliographic Details
Published in:	Revista española de enfermedades digestivas Vol. 115; no. 4; p. 206
Main Authors:	Tejedor, Marta, Delgado, Agustín, Melero, Rosa, Fernández-Alonso, Víctor, Salcedo, Magdalena, Rodríguez-Benítez, Patrocinio
Format:	Journal Article
Language:	English
Published:	Spain 01-04-2023
Subjects:	Antidiuretic Hormone Receptor Antagonists - therapeutic use Benzazepines - therapeutic use Humans Hypertension, Portal - complications Hypertension, Portal - drug therapy Hyponatremia - chemically induced Hyponatremia - etiology Retrospective Studies Tolvaptan - therapeutic use
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Tolvaptan (TVP) is a selective antagonist of vasopressin receptors, approved for the treatment of hyponatremia in SIADH, congestive heart failure (CHF) and cirrhosis. We retrospectively reviewed all cases where TVP was used in a tertiary hospital (January 2012- January 2017). Our aim was to study the use of TVP in real life practice in patients with portal hypertension (PHT) (past history of non-malignant ascites or variceal bleed).
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1130-0108
DOI:	10.17235/reed.2022.9145/2022